John Swisher, PhD
Pulmonary Disease · Knoxville, TNNPI 1083609564
Payments from drug & device makers
Across 747 payments — averaging $3113.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.8M
- United Therapeutics Corporation$313K
- Actelion Pharmaceuticals US, Inc.$131K
- Novartis$20K
- AstraZeneca$18K
- GSK$925
- plus $3K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 45 | $1,839,192 |
| United Therapeutics Corporation | 248 | $312,656 |
| Actelion Pharmaceuticals US, Inc. | 204 | $131,419 |
| Novartis | 2 | $19,738 |
| AstraZeneca(2 entities) | 45 | $18,290 |
| GSK | 53 | $925 |
| Insmed, Inc. | 16 | $437 |
| Grifols USA, LLC | 15 | $326 |
| Bayer | 18 | $325 |
| Regeneron Healthcare Solutions, Inc. | 8 | $291 |
| Amgen | 14 | $249 |
| Boehringer Ingelheim | 12 | $229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $200 |
| Philips North America LLC | 11 | $182 |
| Abbott | 2 | $146 |
| Sanofi | 5 | $138 |
| UCB, Inc. | 2 | $123 |
| Viatris Specialty LLC | 3 | $112 |
| Baxter Healthcare | 6 | $107 |
| Mylan Specialty L.p. | 3 | $86 |
| Gilead | 5 | $80 |
| Sandoz | 3 | $66 |
| Shionogi Inc | 3 | $55 |
| Pfizer | 2 | $37 |
| Liquidia Technologies, Inc. | 2 | $34 |
| Electromed, Inc. | 2 | $32 |
| Pulmonx Corporation | 1 | $25 |
| CMP Pharma, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $20 |
| Johnson & Johnson | 2 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| Phadia US Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$2,325,650 in reported general payments places this provider in the 95th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Knoxville
- Eric WeaverKnoxville$492K
- Rajiv DhandKnoxville$426K
- John CallisonKnoxville$324K
- John PrinceKnoxville$117K
- Isaac BineyKnoxville$73K
- Varun ShahKnoxville$64K
- Benjamin BevillKnoxville$31K
- Bashar BargotyKnoxville$28K
- Zulma SwankKnoxville$24K
- Shannon ByrdKnoxville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.